TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2547138
Drug: Regimen D
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen D (10.0 mg oestriol)
Study: 2547138
Drug: Regimens A
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimens A (2.5 mg piperazine oestrone sulphate) and B (1.25 mg piperazine oestrone sulphate + 5.0 mg oestriol)
Study: 2547138
Drug: All oestrogen
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All oestrogen formulations
Study: 2547138
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration for 7 days
Study: 766041
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nortriptyline (NT) treatment at high plasma levels (less than 180 ng/ml)
Study: 766041
Drug: Evaluation after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation after 6 weeks of NT treatment
Study: 766041
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects of NT treatment
Study: 24815999
Drug: Overall inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall inhalation characteristics
Study: 24815999
Drug: Overall inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall inhaled volumes
Study: 23588939
Drug: Sulfasalazine +
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine + hydroxychloroquine (triple therapy)
Study: 10936835
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral microscopy
Study: 9051544
Drug: High-dose etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose etomidate (HET) 0.5 to 1.7 mg/kg titrated to an early burst suppression pattern
Study: 9051544
Drug: Low-dose etomidate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose etomidate (LET) 0.4 to 0.6 mg/kg titrated to an EEG spectral edge frequency (SEF) of 10 to 12 Hz
Study: 9051544
Drug: Thiopental sodium
Normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental sodium (THIO) 3 to 6 mg/kg titrated to the same EEG endpoint
Study: 8119064
Drug: Long-duration adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-duration adjuvant chemotherapy
Study: 29481630
Drug: Vinflunine 280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinflunine 280 mg/m2 intravenously every 3 weeks (q3w)
Study: 29481630
Drug: Alkylating agent
Normalized name: Alkylating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkylating agent (AA) monotherapy q3w
Study: 24827034
Drug: Low-dose posaconazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose posaconazole (100 mg twice daily)
Study: 24827034
Drug: High-dose posaconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose posaconazole (400 mg twice daily)
Study: 24827034
Drug: Benznidazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benznidazole (150 mg twice daily)
Study: 21917191
Drug: 34 g
Normalized name: Droplet Micron Pen Needles 34 g X 3.5 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 34 g fish pâté (n 44)
Study: 21917191
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml fruit juice (n 38)
Study: 21917191
Drug: three capsules
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: three capsules of concentrated fish oil (n 40)
Study: 20092584
Drug: Basal-bolus regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus regimen with insulin glargine and insulin glulisine
Study: 20092584
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin regimen
Study: 8853248
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily plus repeated laser photocoagulation
Study: 3006449
Drug: Captopril 75
Normalized name: captopril 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 75 mg
Study: 1847704
Drug: Captopril with
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril with Dexamethasone (DXM) 25 mg
Study: 1847704
Drug: Captopril with
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril with Dexamethasone (DXM) 75 mg
Study: 6294263
Drug: Ceftriaxone 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 75 mg/kg
Study: 6294263
Drug: Ceftriaxone 50
Normalized name: ceftriaxone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 50 mg/kg
Study: 26654212
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy for perinatal depression (MBCT-PD)
Study: 25113509
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of 0.33% ropivacaine and normal saline with epinephrine
Study: 22455835
Drug: OCD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCD treatment response
Study: 21595143
Drug: Orthopedic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthopedic treatment including Minimal invasive Therapy (MIT)
Study: 21595143
Drug: Naturopathic 'complex'-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturopathic 'complex'-treatment
Study: 16155268
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g resistant starch/d
Study: 10814606
Drug: High-dose ATP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ATP infusion (75 microg.min(‐1).kg(‐1))
Study: 10814606
Drug: Low-dose ATP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ATP infusion (37-50 microg.min(‐1).kg(‐1))
Study: 9015906
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg o.m. plus clarithromycin 500 mg t.i.d. for 14 days (group L30)
Study: 9015906
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.i.d. plus clarithromycin 500 mg t.i.d. for 14 days (group L60)
Study: 2056290
Drug: Home air-fluidized
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home air-fluidized bed therapy
Study: 19294953
Drug: School-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based intervention program (N = 41) consisting of four 50-minute classes over a 4-week period educating on healthy lifestyle based on cognitive-behavior therapy framework.
Study: 11008725
Drug: 10-mg nitroglycerin
Normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg nitroglycerin patch
Study: 11008725
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Control group C)
Study: 9366699
Drug: Ofloxacin (adults,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (adults, 0.5 mL; children, 0.25 mL) twice daily for 10 days
Study: 9366699
Drug: Cortisporin (adults,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisporin (adults, 0.2 mL; children, 0.15 mL) 4 times daily for 10 days
Study: 1531118
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous maintenance of anaesthesia with an infusion of propofol and increments of alfentanil (Group P)
Study: 3158128
Drug: Lidocaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2 mg/min intravenous infusion following an initial bolus of 200 mg)
Study: 31705526
Drug: Guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 100 mg by subcutaneous injection
Study: 26453914
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AsA) 500 mg; α-tocopherol 300 IU
Study: 24885600
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C infusion plus oral administration of vitamin E during angioplasty, followed by oral doses of vitamins C and E for 84 days
Study: 24885600
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C infusion plus oral administration of vitamin E
Study: 18606481
Drug: 9vPnC‐MnCC (CRM197‐conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9vPnC‐MnCC (CRM197‐conjugated pneumococcal serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F and meningococcal C polysaccharides) given in three doses (3, 4, and 5 months)
Study: 18606481
Drug: 9vPnC‐MnCC (CRM197‐conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9vPnC‐MnCC (CRM197‐conjugated pneumococcal serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F and meningococcal C polysaccharides) given in two doses (3 and 5 months)
Study: 15811481
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg TID
Study: 30484021
Drug: Wet-cupping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet-cupping therapy
Study: 30484021
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (rest and oral medications)
Study: 23601029
Drug: Buccal mucosa
Normalized name: Diazepam 5 MG Buccal mucosa Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal mucosa graft urethroplasty
Study: 21425572
Drug: Xuefu Zhuyu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuefu Zhuyu Capsule (Control)
Study: 21714585
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg (group R)
Study: 21714585
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg plus fenofibrate 200 mg (group RF)
Study: 21714585
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg plus omega 3 fatty acids 2 g daily (group RΩ)
Study: 17402355
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group using a portable computer for daily contact with heart failure clinic
Study: 16215713
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/day) + Metoprolol (50 mg/day)
Study: 16215713
Drug: All drug
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drug therapy groups
Study: 10543315
Drug: PNU-142633F 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-142633F 1.0 mg
Study: 10543315
Drug: PNU-142633F 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-142633F 3.0 mg
Study: 10543315
Drug: PNU-142633F 30
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-142633F 30 mg
Study: 10543315
Drug: PNU-142633F 100
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-142633F 100 mg
Study: 7587604
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with glurenorm and insulin
Study: 2339203
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (marine oil capsules)
Study: 2339203
Drug: Aspirin (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (daily dosages increasing from 162 to 2600 mg)
Study: 6106735
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (Haemophilus influenzae type b capsular polysaccharide)
Study: 25791863
Drug: Pistachio-supplemented diet
Normalized name: Pistachio
DrugBank: Pistachio (DB10559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistachio-supplemented diet (PD, 57 g/d of pistachios daily)
Study: 21098143
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zolpidem alone
Study: 21098143
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zolpidem after 15 days of 400 mg carbamazepine
Study: 16918657
Drug: Rocuronium 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.4 mg x kg(‐1) administered i.v. before intubation (Group R, n = 59)
Study: 15486330
Drug: Intervention (structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (structured nurse assessment, education, treatment recommendations)
Study: 9378840
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of sinistrin
Study: 9378840
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose followed by a 6-hour infusion of sinistrin
Study: 29446195
Drug: Brief motivational
Normalized name: ALCOHOL 300 mL in 375 mL TOPICAL LIQUID [Nelsons Clean Brier Tennessee Handwash]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief motivational interviewing and cognitive-behavioural therapy
Study: 29446195
Drug: Longer term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Longer term motivational interviewing and cognitive-behavioural therapy
Study: 21801476
Drug: B-vitamins (5-methyl-THF
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-vitamins (5-methyl-THF (560 μg); vitamin B₆ (3 mg); vitamin B₁₂ (20 μg))
Study: 21801476
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (600 mg of EPA and DHA at a ratio of 2:1)
Study: 21801476
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for both treatments
Study: 20368566
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (40,000 U weekly during and after chemotherapy)
Study: 2320062
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg, intravenous)
Study: 2320062
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (250 mg three times a day for four weeks)
Study: 23999198
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg and 3.0 mg
Study: 11196760
Drug: Ferric polymaltose
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric polymaltose (6 mg/kg/d)
Study: 11196760
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (6 mg/kg/d)
Study: 6147051
Drug: Oxmetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxmetidine 400 mg
Study: 6147051
Drug: Oxmetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxmetidine 800 mg
Study: 6147051
Drug: Oxmetidine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxmetidine (all doses)
Study: 6147051
Drug: Oxmetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxmetidine (800 mg)
Study: 6147051
Drug: Oxmetidine (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxmetidine (highest dose)
Study: 6147051
Drug: Oxmetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxmetidine (400 mg)
Study: 29266965
Drug: Intensified-dose ICS/LABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified-dose ICS/LABA
Study: 26440923
Drug: 0.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg vitamin D3 per day
Study: 26591679
Drug: Acupuncture-Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-Medicine
Study: 10356137
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) 0.25 mg/kg
Study: 8619455
Drug: Meglumine ioxitalamate
Normalized name: meglumine ioxithalamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine ioxitalamate (100 mL via nasogastric tube)
Study: 8619455
Drug: Standard conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conservative treatment without contrast material
Study: 6094458
Drug: Cefotaxime 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 0.5 g single dose
Study: 6094458
Drug: Cefotaxime 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 0.5 g twice a day for 10 days
Study: 6094458
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g twice or three times a day for 10 days
Study: 31800488
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg mecamylamine
Study: 29651664
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy + surgery
Study: 29651664
Drug: Surgery +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery + adjuvant chemotherapy
Study: 29651664
Drug: Any chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any chemotherapy with surgery
Study: 19380753
Drug: Daily enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily enteral supplementation with zinc, selenium, and glutamine plus parenteral metoclopramide
Study: 11423056
Drug: 5-mg warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg warfarin group
Study: 11423056
Drug: 2.5-mg warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-mg warfarin group
Study: 9421775
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cefuroxime (3 g or 1.5 g)
Study: 9421775
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of vancomycin (1.5 g)
Study: 9421775
Drug: Additional dose
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional dose during cardiopulmonary bypass of cefuroxime
Study: 9421775
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cefuroxime
Study: 9421775
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of vancomycin
Study: 8335738
Drug: Topical fluocinolone
Normalized name: fluocinolone Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluocinolone acetonide ointment (0.025%) diluted by area of application
Study: 8335738
Drug: Topical fluocinolone
Normalized name: fluocinolone Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluocinolone acetonide ointment (0.025%) diluted by volume (1:1 and 1:3)
Study: 8335738
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro method measuring fluocinolone release from diluted ointments
Study: 3117998
Drug: 0.5 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg/d lipid for 5 days (group 1)
Study: 3117998
Drug: 0.5 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg/d increased to 2.0 g/kg/d over 5 days (group 2)
Study: 3117998
Drug: Lipid infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion at 0.5 to 2.0 g/kg/d
Study: 26785406
Drug: HeLP‐her self‐management
Approvals — FDA: no, EMA: no, PMDA: no
Description: HeLP‐her self‐management lifestyle intervention (1 group session, monthly SMS text messages, 1 phone coaching session, program manual)
Study: 25197804
Drug: Intravenous acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acetazolamide (10 mg/kg)
Study: 22252827
Drug: Rifampin 450
Normalized name: rifampin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 450 mg daily
Study: 22252827
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg daily
Study: 10063942
Drug: Policosanol 10
Normalized name: policosanol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 10 mg twice daily
Study: 7886417
Drug: Intracavernosal papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal papaverine hydrochloride (8 mg) plus intraurethral capsaicin (10(‐5) M)
Study: 7886417
Drug: Intracavernosal papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal papaverine hydrochloride (8 mg) plus intraurethral saline infusion
Study: 7886417
Drug: Intraurethral saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraurethral saline solution
Study: 27986972
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (50,000 IU weekly for 12 weeks)
Study: 25651782
Drug: Tofacitinib (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (0.5 mg, 3 mg, 10 mg)
Study: 21903531
Drug: Cetylpyridinium chloride
Normalized name: Cetylpyridinium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetylpyridinium chloride in combination with sodium fluoride
Study: 16310895
Drug: Heparin 1500
Normalized name: Heparine
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin 1500 units
Study: 16310895
Drug: Hydrocortisone 15
Normalized name: hydrocortisone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 15 mg
Study: 16310895
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Heparin and Hydrocortisone
Study: 14600553
Drug: CON (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON (continued weekly training)
Study: 1539506
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (streptokinase)
Study: 1512330
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (rt-PA)
Study: 1539506
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy preceded by acetylsalicylic acid